ASCT-83

ASCT-83 is a synthetic 23-amino acid macrocyclic peptide with a molecular weight of approximately 3 kDa, currently under development by Alcamena Stem Cell Therapeutics for the treatment of neuropathic pain. The drug is formulated as a sterile solution for subcutaneous injection and is designed to provide a targeted therapeutic approach for pain management. Macrocyclic peptides like ASCT-83 are often engineered to offer improved stability and binding affinity compared to their linear counterparts. As of early 2024, ASCT-83 is being evaluated in a Phase 1 first-in-human, randomized, double-blind, placebo-controlled study to assess its safety, tolerability, and pharmacokinetics in healthy adult participants, supporting the design of future clinical trials for neuropathic pain indications.